MCM
SYRE icon

Mainstay Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Mainstay Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40
Closed -$10K – 342
2018
Q3 		$10K Buy
+40
New +$9.34K 0.01% 340

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Mainstay Capital Management's SYRE Position: Q4 2018 in Review

Mainstay Capital Management sold out of Spyre Therapeutics (SYRE) in Q4 2018, closing a stake of 40 shares — an estimated $10K sold.

Mainstay Capital Management first reported a position in SYRE in Q3 2018 and held it in 1 quarter. The position peaked at $10K in Q3 2018. 60 funds tracked by Wall St. Rank hold SYRE as of Q4 2018.

  • Mainstay Capital Management reported no remaining Spyre Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 40 Spyre Therapeutics shares in Q4 2018, an estimated $10K.
  • Mainstay Capital Management first reported a position in Spyre Therapeutics in Q3 2018 and held it in 1 quarter.
  • Mainstay Capital Management's Spyre Therapeutics position peaked at $10K in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.